Stimulation of Cytolytic Activity by Interleukin-10

Journal of Immunotherapy

Volumn 16, Issue 2, 1994, Pages 95-104

  Schwarz, Martin A ^a   Hamilton, Linda D ^a   Tardelli, Lisa ^a   Narula, Satwant K ^a   Sullivan, Lee M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Immunotherapy; Interleukin 10; Lymphokine activated killer cells

Indexed keywords

ALPHA INTERFERON; CHROMIUM 51; GAMMA INTERFERON; INTERLEUKIN 10; RECOMBINANT ALPHA INTERFERON; RECOMBINANT INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 4; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CANCER IMMUNOTHERAPY; CELL STRAIN K 562; COLON CARCINOMA; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; DAUDI CELL; EFFECTOR CELL; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; LARGE GRANULAR LYMPHOCYTE; LYMPHOKINE ACTIVATED KILLER CELL; MELANOMA CELL; MONONUCLEAR CELL; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXICITY, IMMUNOLOGIC; HUMAN; INTERFERON-ALPHA; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKIN-4; KILLER CELLS, LYMPHOKINE-ACTIVATED; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED;

EID: 0028023013     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199408000-00003     Document Type: Article

References (51)

1. Sosman JA, Kohler PC, Hank J, Sondel PM. Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity. J Natl Cancer Inst 1988;80:60-5.
2. Leahy MG, Pitfield D, Popert S, Gallagher CJ, Oliver RTD. Phase I study comparing continuous infusion of recombinant interleukin-2 by subcutaneous or intravenous administration. EurJ Cancer 1992;28A: 1049-51.
3. Heaton KM, Grimm EA. Cytokine combinations in immu-notherapy for solid tumors: a review. Cancer Immunol Im-munother 1993;37:213-9.
4. Rosenberg SA, Lotze MT, Muul LM. Observations on the systemic administration of autologous cytokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. J Immunol 1985;138:1779-85.
5. Szno IM, Clark JW, Smith JW II, et al. Pilot study of interleukin-2 and lymphokine activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon-alpha-2a in patients with metastatic melanoma and renal cell carcinoma. J Natl Cancer Inst 1992;84:929-37.
6. Edwards MJ, Miller FN, Sims DE, Abney DL, Schushke DA, Corey TS. Interleukin 2 acutely induces platelet and neutrophil adherence and macromolecular leakage. Cancer Res 1992;52:3425-31.
7. Fujita S, Puri R, Yu Z-X, Travis WD, Ferrans VJ. An ultra-structural study of in vivo interactions between lymphocytes and endothelial cells in the pathogenesis of the vascular leak syndrome induced by interleukin-2. Cancer 1991;68:2169-74.
8. Nagasawa M, Ohshiba A, Junichi Y. Effect of recombinant interleukin-5 on the generation of cytotoxic T cells. Cell Immunol 1991;133:317-28.
9. Stotter H, Custer MC, Bolton ES, Guedez L, Lotze MT. L-7 induces human lymphokine-activated killer activity and is regulated by IL-4. J Immunol 1991;146:150-5.
10. Alderson MR, Sassenfeld HM, Widmer MB. Interleukin-7 enhances cytolytic T lymphocyte generation and induces lymphocyte-activated killer cells from human peripheral blood. J Exp Med 1990;172:577-87.
11. +NK cells. J Immunol 1992;148:2429-36.
12. Gately M, Desai BB, Wolitky AG, et al. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol 1991;147:874-82.
13. Robertson MJ, Soiffer RJ, Wolf SP, et al. Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J Exp Med 1992;175:779-88.
14. +natural killer cells stimulated with interleukin-2, interleukin-7 and interleukin-12. Eur J Immunol 1993;23:1831-8.
15. Nakashima Y, Mita S, Takatsu K, Ogawa M. Interleukin-5 induces tumor suppression by peritoneal exudate cells in mice. Cancer Immunol Immunother 1993;37:227-32.
16. Fiorentino DF, Bond MW, Mossman TR. Two types of mouse helper T cells. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989;170:2081-95.
17. Spits H, de Waal Malefyr R. Functional characterization of human IL-10. Int Arch Allergy Appl Immunol 1992;99:8-15.
18. Mossman TR. Regulation of immune responses of T cells with different cytokine secretion phenotypes: role of a new cytokine, cytokine synthesis inhibitory factor (IL-10). Int Arch Allergy Appl Immunol 1991;94:110-5.
19. de Waal Malefyt R, Haanen J, Spits H, et al. Interleukin-10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via down-regulation of class-II major histocompatability complex expression. J Exp Med 1991;174:915-24.
20. Bejarano M-T, de Waal Malefyt R, Abrams JS, et al. IL-10 inhibits allogeneic proliferative and cytotoxic T cell responses generated in primary MLC. Int Immunol (in press).
21. Gerard C, Bruyns C, Marchant A, et al. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 1993;177:547-50.
22. Chen W-F, Zlotnik A. IL-10: a novel cytotoxic T cell differentiation factor. J Immunol 1991;147:528-34.
23. Hsu D-W, Moore KW, Spits H. Differential effects of IL-4 and IL-10 on IL-2-induced IFN-γ synthesis and lymphokine-activated killer activity. Int Immunol 1992;4:563-9.
24. Spits H, Yssel H, Paliard X, Kastelein R, Figdor C, de Vries JE. IL-4 inhibits IL-2 mediated induction of human lympho-kine activated killer cells, but not the generation of antigen specific cytotoxic T lymphocytes in mixed lymphocytes in mixed leukocyte cultures. J Immunol 1988;141:29-36.
25. Shau H, Golub SH. Depletion of NK cells with the lysoso-motrophic agent L-leucine methyl ester and in vitro generation of NK activity from NK precursor cells. J Immunol 1985;134:1136-41.
26. Pross HF, Baines MG, Rubin P, Shragge P, Patterson MS. Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity. J Clin Immunol 1981;l:51-63.
27. Stotter H, Lotze MT. Human lymphokine-activated killer cell activity. Role of IL-2, IL-4, and IL-7. Arch Surg 1991;126:1525-30.
28. Hiserodt JC. Lymphokine-activated killer cells: biology and relevance to disease. Cancer Invest 1993;11:420-39.
29. Salvo G, Samoggia P, Masciulli R, et al. Interleukin-2 bolus therapy induces immediate and selective disappearance from peripheral blood of all lymphocyte subpopulations displaying natural killer activity: role of cell adhesion to endot-helium. Eur J Cancer 1992;28A:818-25.
30. Kedar E, Rutkowski Y, Leshem B. Chemo-immunotherapy of murine solid tumors: enhanced therapeutic effects by interleukin-2 combined with interferon-7 and the role of specific T cells. Cancer Immunol Immunother 1992;35:63-8.
31. Figlin RA, Belldegrun A, Moldawer N, Zeffren J, deKernion J. Concomitant administration of recombinant human interleukin-2 and recombinant interferon-alpha-2A: an active outpatient regimen in metastatic renal cell carcinoma. J Clin Oncol 1992;10:414-21.
32. Thomas H, Barton C, Saini A, et al. Sequential interleukin-2 and alpha interferon for renal cell carcinoma and melanoma. Eur J Cancer 1992;28A:1047-9.
33. Vogelzang NJ, Lipton A, Figlin RA. Subcutaneous interleukin-2 plus interferon alpha-2a in metastatic renal cancer: an outpatient multicenter trial. J Clin Oncol 1993;11:1809-16.
34. Higuchi CM, Thompson JA, Lindgren CG, et al. Induction of lymphokine-activated killer activity by interleukin-4 in human lymphocytes preactivated by interleukin 2 in vivo or in vitro. Cancer Res 1989;49:6487-9.
35. McAdam AJ, Yeh K-Y, Pulaski BA, Frelinger JG, Lord EM. Interleukin-3 inhibits the generation of non-specific killers by interleukin-2. J Immunother 1993;14:293-7.
36. Colquhoun SD, Economou JS, Shau H, Golub SH. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues. J Surg Res 1993;55:486-92.
37. Mulé JJ, Schwarz SL, Roberts AB, Sporn MB, Rosenberg SA. Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells. Cancer Immunol Immunother 1988;26:95-9.
38. Blay JY, Bertoglio J, Fradelizi D, Chouaib S. Functional interactions of IL-2 and TNF in the differentiation of LGL in LAK effectors. Int J Cancer 1989;44:598-604.
39. Jewett A, Bonavida B. Pivotal role of endogenous TNF-α in the IL-2-driven activation and proliferation of the functionally immature NK free subset. Cell Immunol 1993;151:257-69.
40. Spagnoli GC, Juertic A, Schultz-Thater E, et al. On the relative roles of interleukin-2 and interleukin-10 in the generation of lymphokine-activated killer cell activity. Cell Immunol 1993;146:391-405.
41. Naume B, Shalaby R, Lesslauer W, Espevik T. Involvement of the 55- and 75-kDa tumor necrosis factor receptors in the generation of lymphokine-activated killer cell activity and proliferation of natural killer cells. J Immunol 1991;146:3045-8.
42. Rosenberg SA, Lotze MT, Yang JC, et al. combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989;7:1863-74.
43. Escudier B, Farace F, Angevin E, et al. combination of interleukin-2 and gamma interferon in metastatic renal cell carcinoma. Eur J Cancer 1993;29A:724-8.
44. Lipton A, Harvey H, Givant E. Interleukin-2 and interferon-α-2a outpatient therapy for metastatic renal cell carcinoma. J Immunother 1993;13:122-9.
45. Fluckiger A-C, Garrone P, Durand I, et al. IL-10 upregulates functional high affinity IL-2 receptors on normal and leuke-mic B lymphocytes, (in press).
46. Tornita Y, Watanabe H, Kobayashi H, et al. Interferon-γ but not tumor necrosis factor α decreases susceptibility of human renal cell cancer cell lines to lymphokine-activated killer cells. Cancer Immunol Immunother 1992;35:381-7.
47. Swisher SG, Economou JS, Holmes E, Golub S. TNF-α and IFN-γ reverse IL-4 inhibition of cytokine-activated killer cell function. Cell Immunol 1990;128:450-61.
48. Tomizawa K, Ishizaka A, Nakanishi M, Kojima K, Sak-iyama Y, Matsumoto S. Interleukin-4 down regulates the IL2Rp70-75 expressed on human natural killer cells. Immunol Lett 1992-,32:101-4.
49. Bosse D, Ades E. Down-regulation of interleukin-2 receptor expression on natural killer cells/large granular lymphocytes by interleukin-4. Pathobiology 1992;60:72-5.
50. Golumbek PT, Lazenby AJ, Levinsky HI, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991;254:713-6.
51. Richter G, Kruger-Krasagakes S, Hein G, et al. Interleukin 10 transfected into Chinese hamster ovary cells prevents growth and macrophage infiltration. Cancer Res 1993;53:4134-7.